Tumor necrosis factor (TNF) toxicity was induced in vivo by intravenous administration of 15 pg of recombinant murine TNF-a per kg to galactosamine-sensitized mice. Within 8 h, the animals developed a fulminant hepatitis. Intravenous administration of 0.5 mg of colchicine per kg at 19 and 4 h prior to TNF challenge protected the animals against hepatitis. Lipopolysaccharide (LPS)-stimulated, bone marrow-derived macrophages from C3H/HeN mice released significant amounts of TNF in vitro. When such macrophages were intravenously given to LPS-resistant galactosamine-sensitized C3H/HeJ mice, these animals died within 24 h.
against galactosamine-LPS-induced hepatitis by pretreatment with colchicine, TNF was still released into the blood. We conclude from our findings that the in vivo protection by colchicine is mediated by blocking TNF action on target cells while the effector cells of LPS toxicity, i.e., the macrophages, remain responsive.
Endotoxins (lipopolysaccharides [LPS]
) from gram-negative bacteria induce shock in humans and animals, a state which is characterized by fever, hypotension, intravascular coagulation, and finally multiorgan failure. For the study of toxic LPS effects in vivo, two experimental mouse models are available. Besides the LPS-induced lethality model, which requires administration of about 150 ,ug of LPS per mouse (100% lethal dose within 48 h) (3, 13) , galactosamine (GalN) sensitization is frequently used to study LPS lethality (13) . GalN sensitizes NMRI mice about 30,000-fold towards LPS (13) . This amino sugar is known to block selectively hepatic transcription, i.e., indirectly hepatic protein synthesis (5) , and to result in organ failure only in liver as a consequence of LPS toxicity. GalN-LPS-treated mice develop a severe hepatitis within 8 h which allows quantification of the extent of hepatic lesions by measurement of serum transaminases (27) . As for LPS-induced lethality (3), anti-mouse tumor necrosis factor (TNF) antiserum protects also against GalN-LPS-induced hepatitis (24) . At present, TNF-a is regarded as the predominant cytokine which mediates LPS-induced cytotoxicity and organ failure (3). In both models, i.e., LPS lethality and GalN-LPS-induced hepatitis, TNF was shown to substitute for LPS in inducing lethality (17, 25) . Therefore, the GalN model allows the study of TNF-induced toxicity at extremely low doses in a model analogous to TNF-induced shock.
In previous studies it has been shown that macrophages play a crucial role in the host response to endotoxins (12, 22 macological intervention possibilities against LPS-induced organ injury. Pretreatment with 5-lipoxygenase inhibitors (15, 27) , with inhibitors of postischemic, oxygen-radicalmediated tissue injury (28), or with serine-protease inhibitors (20) successfully prevented LPS-induced hepatitis in GalNsensitized mice. Any of these agents protecting against LPS, however, failed to protect against injury induced by challenge with recombinant TNF-a instead of LPS (20, 25) . Since animals which had been protected against LPS by these interventions did not release significant amounts of TNF into the circulation, the observed protection was ascribed to an inhibition of LPS-induced TNF release (20, 21, 23) . The alkaloid colchicine is known to affect the functional capabilities of leukocytes related to their mobility (10) . On the other hand, a potential inhibition of microtubular function needed to internalize the TNF receptor (16, 26) Teflon film bags (Heraeus, Hanau, Germany) as described previously (9) . The culture medium contained the highglucose formulation of Dulbecco's modified Eagle medium (GIBCO BRL GmbH, Karlsruhe, Germany), 10% fetal calf serum (FCS), 5% horse serum, 0.01 mM sodium pyruvate (GIBCO), 50 ,uM 2-mercaptoethanol (Roth), 50 U of penicillin, 50 ,ug of streptomycin (Seromed, Berlin, Germany) per ml, and 30% L-cell-conditioned medium (18) containing colony-stimulating factor. L-cell (strain L929S)-conditioned medium was prepared as described previously (9) . After 10 days of culture, the cells were harvested by centrifugation at 4°C and washed extensively with cold pyrogen-free PBS. According to previously published data, the final population of cells obtained by the method described above contained at least 96% macrophages (19 Enzyme assay procedure. ALT activities in serum were determined in the clinical routine enzyme activity release assay as described in reference 2, using the decrease of NADH (A334) for photometric evaluation.
Statistics. The results were analyzed according to Student's t test and are given as mean values ± standard errors of the mean. P c 0.05 was considered significant.
RESULTS
Colchicine protects against GalN-LPS-induced hepatitis in mice. As reported previously, intraperitoneal administration of 5 ,ug of Salmonella abortus equi LPS per kg to NMRI mice sensitized by 700 mg of GalN per kg led to induction of fulminant hepatitis within 8 h as assessed by determination of serum transaminases (27) . As indicated in Table 1 , GalN-LPS-injured mice released high amounts of TNF into the circulation as determined 1 h after challenge. Because a long period of time is needed for impairment of microtubular function and shortly before challenge a pharmacokinetic reload is necessary, we decided to pretreat animals with the microtubule disrupting agent colchicine 19 and 4 h before LPS challenge. Administration of 0.5 mg of colchicine per kg according to this regimen protected against GalN-LPSinduced hepatitis (Table 1) . Compared with amounts in untreated controls, large amounts of TNF were still systemically present in colchicine-protected mice, even though the amounts were significantly smaller than in animals which had received LPS alone. These results prompted us to further investigate the protective effect of colchicine against TNF-mediated cytotoxicity. Table 2 ). The macrophages produced large amounts of TNF upon LPS stimulation (Table 3) . To exclude the possibility that the colchicine preparation contained minute amounts of LPS which could have induced tolerance against TNF toxicity (11) we performed the following in vivo experiments with the LPS-resistant C3H/HeJ mouse strain.
The results in Table 2 show that preventative pretreatment of mice with colchicine protected against TNF-cx-induced hepatitis as well as against LPS-induced, macrophage-medi- GalN-TNF-cx, the ALT detected was 1,780 + 560 U/liter (n = 4), whereas for cytochalasin B + GalN-TNF-ot, the ALT detected was 75 + 24 U/liter (n = 4) (P c 0.05).
LPS-inducible TNF release ex vivo is not suppressed by colchicine. To examine the cellular site of colchicine action, we studied the inhibitory capacity of colchicine in the following ex vivo experiments shown in Table 3 .
LPS-responsive bone marrow-derived macrophages from C3H/HeN mice were preincubated for 40 min with either 20 or 200 ,uM colchicine. This corresponds to a previously used incubation protocol, in which preincubation by 20 ,uM colchicine for 30 min had resulted in enhanced survival of murine tumorigenic fibroblasts (L-M cells) exposed to tumor necrosis serum (16) . The results in Table 3 show that neither 20 nor 200 ,uM colchicine significantly inhibited the LPSinducible TNF release from macrophages. Accordingly, similar to the injection of LPS-stimulated macrophages, the injection of colchicine-preincubated, LPS-stimulated macrophages into GalN-sensitized C3HJHeJ mice led to 100% lethality within 24 h.
To have comparable colchicine exposure times in vivo and in vitro, bone marrow-derived macrophages were incubated for 19 h with either 20 or 200 ,uM colchicine before LPS stimulation. Under these conditions as well, colchicine did not inhibit the LPS-induced TNF release (data not shown).
Cell viability, which was determined by the trypan blue exclusion method, amounted to 90 to 97% and was not affected by either pretreatment.
The lack of an inhibitory effect of colchicine on LPSstimulated TNF release from macrophages suggests that it is not the effector cells, i.e., peripheral macrophages, which are suppressed by colchicine, thereby leading to in vivo protection against TNF. This in vitro observation corroborates our conclusion, drawn from the in vivo experiments shown in Table 2 , that colchicine-mediated protection acts on the target cell(s) of TNF-ao.
DISCUSSION
Colchicine is an alkaloid of Colchicum autumnale. It has been known for a long time as a treatment against gouty arthritis. Clinically, the drug provides dramatic relief of gout attacks and is an effective prophylactic agent against acute episodes (10) . The antiinflammatory effect of colchicine is thought to be due to an inhibition of the migration of granulocytes into inflamed areas, i.e., into the joints. The mechanistic rationale may be that granulocyte migration is inhibited because of depolymerization and disappearance of the fibrillar microtubules following colchicine administration (10) .
On the other hand, cytochalasins represent a group of fungal metabolites also affecting the cytoskeleton of cells. These compounds bind to actin and thereby cause inhibition of polymerization and depolymerization of actin filaments in vitro (4) . The present study shows that compounds known to inhibit cytoskeleton functions prevented the in vivo toxicity of TNF. Since in practical pharmacological terms colchicine seems more important as an antiinflammatory agent, we concentrated on this drug.
For the interpretation of our in vivo findings, various in vitro studies provide several alternative explanations. A recent study (7) demonstrated the decrease of TNF-a receptors brought about by colchicine as a consequence of microtubule depolymerization. This effect seemed to be specific for TNF-a receptors, since binding of gamma interferon was not affected by colchicine. However, the study showed also that cytochalasins did not alter TNF receptor density on macrophages as colchicine did. Therefore, the protective effect of colchicine and cytochalasin B described here may depend on a different mechanism. It has been shown that 125I-TNF, bound to a target cell, is internalized by receptor-mediated endocytosis and subsequently degraded to acid-soluble products (1) . Moreover, the TNFsensitive murine tumorigenic fibroblast cell line L-M (CCL VOL. 60, 1992 on August 28, 2017 by guest http://iai.asm.org/ Downloaded from 1.2) was protected against TNF-induced cell killing by microtubule disrupting agents like colchicine, by microfilament disrupting agents like cytochalasins, or by lysosomotropic agents like chloroquine or leupeptin (16, 26) . These findings suggest that colchicine acts by inhibiting TNF internalization followed by delivery to lysosomes, i.e., an event which seems to be essential in the cytolytic mechanism of TNF.
Interestingly, the plant-derived antitumor drug taxol, which is known to inhibit depolymerization of tubulin at a site different from colchicine, reduced TNF receptors and triggered TNF release from macrophages (6) . That study provided evidence that taxol and LPS have a common genetic basis connected to cytoskeleton responses upon LPS activation. Thus, this observation represents a principle different from the one reported here.
The obvious conclusion that inhibition of neutrophil migration by colchicine might underlie its protective properties seems not to hold true; in a recent study we showed that neutrophilia and lymphopenia inducible by LPS or TNF-ot in mice do not correlate with toxicity and occur even after administration of anti-mouse TNF antiserum (24) . Conversely, leukocyte activation by phorbol ester, zymosan, platelet-activating factor, or formyl-methionyl-leucyl-phenylalanine methyl ester failed to induce hepatitis in GaiNsensitized mice (24) . It therefore appears that leukocyte alterations (or their inhibition, e.g., by colchicine) are not the cause of LPS or TNF-a toxicity (or protection against it) but rather a consequence.
The in vitro observations of colchicine-TNF antagonism now have been extended in vivo by showing a protection by the alkaloid against hepatotoxic and lethal effects of TNF. We tend to explain our results rather by assuming a block of TNF-postreceptor signalling in the presence of colchicine than via downregulation of TNF-ao receptors on target cells. The inhibition of TNF internalization represents such a mechanism which we consider to be likely. Since colchicine did not prevent production of TNF by LPS-stimulated cells, the drug may also be a useful tool for further studies on the mechanism of TNF toxicity in vivo.
